compound

Antiasthmatic Compound 1 is an antiasthmatic agent.

Antimicrobial Compound 1 is an alkyl pyridinium compound with Tail 12C, Head 4-carboxyl. Antimicrobial Compound 1 exhibits antimicrobial activities against B. subtilis and E. coli.

Antibacterial compound 1 is an antibacterial compound.

Antibacterial compound 2 is a potent antimicrobial agent effective against many human veterinary pathogens, inhibiting multi-drug resistant staphylococci, enterococci and streptococci, as well as anaerobic bacteria.

NPS ALX Compound 4a hydrochloride(1:1) is a potent and selective 5-hydroxytryptamine6 (5-HT6) receptor antagonist, with an IC50 of 7.2 nM and a Ki of 0.2 nM.

Neuromuscular-targeting compound 1 can be used to study muscular dystrophy and neuromuscular-related diseases.

Cancer-Targeting Compound 1 can be used in the study of hormone-related cancers, including the treatment or prevention of fibroids, uterine leiomyomas, polycystic ovarian syndrome, or hormone-dependent Cancer, among others.

Asthma relating compound 1 is a potential anti-asthma compound.

Neuromuscular Disorder-Targeting Compound 1 is utilized in research for neuromuscular disorders, including chronic fatigue syndrome and fibromyalgia syndrome symptoms.

NPS ALX Compound 4a is a potent and selective antagonist of the 5-HT6 receptor with an IC50 of 7.2 nM.

NPS ALX Compound 4a dihydrochloride is a potent and selective antagonist of the 5-HT6 receptor with an IC50 of 7.2 nM.

Neurodegenerative Disorder-Targeting Compound 1 is a calpain inhibitor [1].

Arrhythmias-Targeting Compound 1 is a compound. It is used in the research of arrhythmias.

Compound 48/80 trihydrochloride (C48/80 trihydrochloride) is a mixture of N-methyl-p-methoxyphenethylamine and formaldehyde produced via a condensation reaction. It acts as a mast cell degranulator and histamine releaser and inhibits phosphatidylinositol-specific phospholipase C activity in human platelets.

Arrhythmic-Targeting Compound 1, used for arrhythmic disease, contains nitrogen-containing spirocycles.

Compound 2 is used for the research of metabolic bone diseases.

Urinary Incontinence-Targeting Compound 1, used in the research of urinary incontinence, is a sulfonanilide derivative.

MreB Perturbing Compound A22 hydrochloride is an inhibitor of MreB, an actin-like bacterial protein, and has been proved to be an antibiotic adjuvant. MreB Perturbing Compound A22 hydrochloride inhibition of MreB disrupts the bacterial actin cytoskeleton, which can cause an increase in cell permeability and altered transport.

Compound 401 (2-morpholino-4H-pyrimido[2,1-a]isoquinolin-4-one) is a synthetic DNA-PK inhibitor (IC50 = 0.28 μM) that also targets mTOR but not PI3K.

Compound C108 is an inhibitor of GTPase-activating protein SH3 domain-binding protein 2 (G3BP2). Compound C108 can be used in studies about breast tumors and esophageal squamous cell carcinoma.

γ-Secretase-IN-1 is a potent γ-secretase inhibitor that displays partial antiproliferative activity on T-47D cells and inhibits β-amyloid(40), β-amyloid(42), and Notch γ-secretase cleavage.

POL1-IN-1 (Compound 3A) can effectively inhibit the transcription of RNA polymerase I in the A375 malignant melanoma cell line but has no effect on polymerase II.

Neuraminidase-IN-1 (Compound Y-1) is a novel neuraminidase inhibitor.

Compounds 35 are superior inhibitors of Ebola (Mayinga) and Marburg (Angola) infectious viruses.